Preclinical and Clinical Evidence of Therapeutic Agents for Paclitaxel-Induced Peripheral Neuropathy

• Published in: International journal of molecular sciences Vol. 22; no. 16; p. 8733
• Main Authors: Kawashiri, Takehiro, Inoue, Mizuki, Mori, Kohei, Kobayashi, Daisuke, Mine, Keisuke, Ushio, Soichiro, Kudamatsu, Hibiki, Uchida, Mayako, Egashira, Nobuaki, Shimazoe, Takao
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 13.08.2021; MDPI
• Subjects: adverse effects; Animal models; Antioxidants; Breast; Cannabinoid receptors; Cannabinoids; Chemical compounds; Chemotherapy; clinical evidence; Clinical medicine; Clinical trials; Cytokines; Drug development; Drug dosages; Drugs; Endometrium; Fatty acids; Inflammation; Inflammatory response; Ion channels; Kinases; Narcotics; Nervous system; Neuroprotection; Neurotoxicity; Oxidative stress; Paclitaxel; Pain; Pancreatic cancer; Peripheral neuropathy; Pharmacology; preclinical data; Proteins; Review; Transient receptor potential proteins; Tumor necrosis factor-TNF
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms22168733

Paclitaxel is an essential drug in the chemotherapy of ovarian, non-small cell lung, breast, gastric, endometrial, and pancreatic cancers. However, it frequently causes peripheral neuropathy as a dose-limiting factor. Animal models of paclitaxel-induced peripheral neuropathy (PIPN) have been established. The mechanisms of PIPN development have been elucidated, and many drugs and agents have been proven to have neuroprotective effects in basic studies. In addition, some of these drugs have been validated in clinical studies for their inhibitory PIPN effects. This review summarizes the basic and clinical evidence for therapeutic or prophylactic effects for PIPN. In pre-clinical research, many reports exist of neuropathy inhibitors that target oxidative stress, inflammatory response, ion channels, transient receptor potential (TRP) channels, cannabinoid receptors, and the monoamine nervous system. Alternatively, very few drugs have demonstrated PIPN efficacy in clinical trials. Thus, enhancing translational research to translate pre-clinical research into clinical research is important.